RESUMEN
BACKGROUND: Elevated ApoA1 levels have been associated with decreased dementia risk. The A-allele of the APOA1 -75G/A promoter polymorphism has been associated with elevated ApoA1 levels. OBJECTIVE: We sought to investigate the effect of the APOA1 -75G/A promoter polymorphism on cognitive performance in patients with multiple sclerosis (MS). METHODS: A total of 138 patients with MS and 43 controls were studied and underwent neuropsychological assessment with Rao's Brief Repeatable Battery and the Stroop test. All patients were genotyped for APOA1. RESULTS: APOA1 A-allele carriers displayed superior overall cognitive performance compared with non-carriers (P 0.008) and had a three-fold decrease in the relative risk of overall cognitive impairment (OR 0.29, 95% CI 0.11-0.74). Regarding performance on individual cognitive domains, although APOA1 A-allele carriers performed better than non-carriers on all tests, this was significant only for semantic verbal fluency and the Stroop interference task (P 0.036 and 0.018, respectively). CONCLUSIONS: We found an association of the APOA1 -75G/A promoter polymorphism with cognitive performance in MS. This effect was most prominent on semantic verbal fluency and the Stroop interference task.
Asunto(s)
Apolipoproteína A-I/genética , Trastornos del Conocimiento/genética , Cognición , Esclerosis Múltiple/genética , Polimorfismo Genético , Adulto , Trastornos del Conocimiento/epidemiología , Femenino , Predisposición Genética a la Enfermedad/epidemiología , Genotipo , Grecia/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/epidemiología , Pruebas Neuropsicológicas , Regiones Promotoras Genéticas/genética , Factores de Riesgo , Aprendizaje VerbalRESUMEN
OBJECTIVE: To investigate the effect of APOE epsilon4 on different cognitive domains in a population of Greek patients with multiple sclerosis (MS). METHODS: A total of 125 patients with MS and 43 controls were included in this study and underwent neuropsychological assessment with Rao's Brief Repeatable Battery. All patients with MS were genotyped for APOE. The effect of APOE epsilon4 on different cognitive domains was investigated. RESULTS: Fifty-one percent of patients with MS were cognitively impaired. E4 carriers had a sixfold increase in the relative risk of impairment in verbal learning vs noncarriers (OR 6.28, 95% CI 1.74 to 22.69). This effect was domain-specific and was not observed in other cognitive domains assessed by the battery. CONCLUSION: We found an association of APOE epsilon4 with impaired verbal learning in patients with multiple sclerosis.